IGF1 and metabolic dysfunction-associated steatotic liver disease: In addition to anti-steatotic effects in animal models of NAFLD, recent reports also have demonstrated that a series of fibrosis signaling pathways in the liver were down-regulated by EGCG treatment,(14) and that EGCG prevents obesity-related liver tumorigenesis by inhibiting the IGF/IGF-1R axis and attenuating chronic inflammation.(15) Although the efficacy of EGCG for NAFLD with a wide range of stages from fatty liver to liver cancer is clear in animal models, it is regretted that no clinical studies have been completed on humans.